# Migraine

**VERSION:** 1.0
**CREATED:** January 29, 2026
**REVISED:** January 29, 2026
**STATUS:** Complete

---

**DIAGNOSIS:** Migraine / Status Migrainosus

**ICD-10:** G43.909 (Migraine, unspecified, not intractable), G43.919 (Migraine, unspecified, intractable), G43.901 (Migraine, unspecified, not intractable, with status migrainosus), G43.911 (Migraine, unspecified, intractable, with status migrainosus), G43.109 (Migraine with aura, not intractable), G43.709 (Chronic migraine without aura, not intractable)

**SYNONYMS:** Migraine headache, migraine with aura, migraine without aura, classic migraine, common migraine, status migrainosus, intractable migraine, refractory migraine, chronic migraine, menstrual migraine, vestibular migraine, hemiplegic migraine, retinal migraine, basilar migraine

**SCOPE:** Evaluation and management of acute migraine, status migrainosus, and chronic migraine in adults. Covers abortive therapy, rescue treatment for refractory attacks, and preventive medication initiation. Includes special considerations for pregnancy and medication overuse. Excludes secondary headache disorders, cluster headache, and tension-type headache.

---

**DEFINITIONS:**
- **Migraine:** Recurrent headache disorder manifesting in attacks lasting 4-72 hours with unilateral location, pulsating quality, moderate-severe intensity, aggravation by activity, and associated nausea/vomiting or photo/phonophobia
- **Status Migrainosus:** Debilitating migraine attack lasting >72 hours
- **Chronic Migraine:** ≥15 headache days/month for >3 months, with migraine features on ≥8 days/month
- **Medication Overuse Headache (MOH):** Headache occurring ≥15 days/month in patient with pre-existing headache using acute medications regularly for >3 months

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------|:--:|:----:|:---:|:---:|-----------|----------------|
| CBC | URGENT | ROUTINE | ROUTINE | - | Rule out anemia, infection | Normal |
| CMP | URGENT | ROUTINE | ROUTINE | - | Electrolyte abnormalities, renal function | Normal |
| hCG (women of childbearing age) | STAT | STAT | ROUTINE | - | Pregnancy status affects treatment options | Document status |
| TSH | - | ROUTINE | ROUTINE | - | Thyroid dysfunction can cause headache | Normal |
| Magnesium | URGENT | ROUTINE | ROUTINE | - | Low levels may contribute to migraines | >1.8 mg/dL |

### 1B. Extended Workup (Second-line)

| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------|:--:|:----:|:---:|:---:|-----------|----------------|
| ESR/CRP | URGENT | ROUTINE | ROUTINE | - | If GCA or inflammatory cause suspected (>50 years, new onset) | Normal |
| Vitamin D | - | ROUTINE | ROUTINE | - | Deficiency associated with migraine frequency | >30 ng/mL |
| Ferritin | - | ROUTINE | ROUTINE | - | Iron deficiency associated with migraine | >50 ng/mL |
| Homocysteine | - | - | EXT | - | Elevated levels associated with migraine with aura | Normal |

### 1C. Rare/Specialized

| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------|:--:|:----:|:---:|:---:|-----------|----------------|
| Lumbar puncture | URGENT | URGENT | - | - | Thunderclap headache, suspected SAH, IIH, meningitis | See LP section |
| Autoimmune panel (ANA, etc.) | - | EXT | EXT | - | If vasculitis or autoimmune cause suspected | Negative |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| CT head without contrast | STAT | URGENT | - | - | If thunderclap, worst headache, focal deficits, altered mental status | Rule out hemorrhage, mass | None in emergency |
| MRI brain without contrast | - | ROUTINE | ROUTINE | - | New headache pattern, focal features, refractory to treatment | Normal; rule out structural cause | Pacemaker, metal implants |

### 2B. Extended

| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| MRI brain with and without contrast | - | ROUTINE | ROUTINE | - | If mass, infection, or inflammation suspected | Rule out enhancement | Contrast allergy, renal disease |
| MRV or CT venogram | URGENT | URGENT | - | - | Suspected cerebral venous thrombosis | Patent venous sinuses | Per modality |
| MRA head | - | ROUTINE | ROUTINE | - | Suspected vasculopathy, aneurysm | Normal vasculature | Per modality |
| ECG | STAT | STAT | - | - | Prior to DHE or triptan use | Normal QTc, no ischemia | None |

### LUMBAR PUNCTURE

**Indication:** Thunderclap headache, suspected SAH (CT negative), suspected IIH (papilledema), suspected meningitis, atypical features

**Timing:** URGENT after CT excludes mass effect

| Study | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|-------|:--:|:----:|:---:|:---:|-----------|----------------|
| Opening pressure | STAT | STAT | - | - | IIH diagnosis | 10-20 cm H2O (elevated >25 suggests IIH) |
| Cell count (tubes 1 and 4) | STAT | STAT | - | - | Infection, SAH | WBC <5; RBC 0 or clearing |
| Protein | STAT | STAT | - | - | Infection, inflammation | 15-45 mg/dL |
| Glucose | STAT | STAT | - | - | Infection | >60% serum |
| Xanthochromia | STAT | STAT | - | - | SAH if CT negative | Negative |
| Gram stain and culture | STAT | STAT | - | - | Bacterial meningitis | No organisms |
| CSF meningitis panel | URGENT | URGENT | - | - | Viral/bacterial pathogens | Negative |

---

## 3. TREATMENT

### 3A. Acute/Abortive Treatment - Mild-Moderate Attacks

| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |
|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|
| Acetaminophen | - | ROUTINE | ROUTINE | - | 1000 mg PO once, max 3000 mg/day | Hepatic disease, chronic alcohol use | LFTs if frequent use |
| Ibuprofen | - | ROUTINE | ROUTINE | - | 400-800 mg PO once | Renal disease, GI bleeding, aspirin allergy | Renal function |
| Naproxen sodium | - | ROUTINE | ROUTINE | - | 500-825 mg PO once | Same as ibuprofen | Renal function |
| Aspirin | - | ROUTINE | ROUTINE | - | 900-1000 mg PO once | Bleeding disorder, aspirin allergy | Bleeding |
| Excedrin (ASA/APAP/caffeine) | - | - | ROUTINE | - | 2 tablets PO once | Per components | Risk of MOH |

### 3B. Acute/Abortive Treatment - Moderate-Severe Attacks (Triptans)

| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |
|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|
| Sumatriptan SC | STAT | STAT | - | - | 6 mg SC once; may repeat in 2h; max 12 mg/24h | CAD, stroke/TIA, uncontrolled HTN, hemiplegic/basilar migraine, pregnancy | Chest tightness, BP |
| Sumatriptan PO | - | ROUTINE | ROUTINE | - | 50-100 mg PO once; may repeat in 2h; max 200 mg/24h | Same as SC | Same |
| Sumatriptan nasal | URGENT | ROUTINE | ROUTINE | - | 20 mg intranasal; may repeat in 2h; max 40 mg/24h | Same as SC | Same |
| Rizatriptan | - | ROUTINE | ROUTINE | - | 5-10 mg PO (ODT available); may repeat in 2h; max 30 mg/24h | Same; 5 mg if on propranolol | Same |
| Eletriptan | - | ROUTINE | ROUTINE | - | 40 mg PO; may repeat in 2h; max 80 mg/24h | Same; severe hepatic impairment | Same |
| Zolmitriptan | - | ROUTINE | ROUTINE | - | 2.5-5 mg PO or nasal; may repeat in 2h; max 10 mg/24h | Same | Same |

### 3C. Acute/Abortive Treatment - CGRP Antagonists (Gepants)

| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |
|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|
| Ubrogepant | - | ROUTINE | ROUTINE | - | 50-100 mg PO; may repeat in 2h; max 200 mg/24h | CYP3A4 inhibitors; no cardiovascular contraindications | LFTs periodically |
| Rimegepant | - | ROUTINE | ROUTINE | - | 75 mg PO once daily; ODT formulation | CYP3A4 inhibitors | LFTs periodically |
| Zavegepant nasal | - | ROUTINE | ROUTINE | - | 10 mg intranasal once daily | None significant | Local irritation |

### 3D. ED/Inpatient Treatment - Status Migrainosus ("Headache Cocktail")

| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |
|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|
| IV fluids | STAT | STAT | - | - | NS or LR 1L bolus, then 75-125 mL/hr | Heart failure, volume overload | I/O |
| Prochlorperazine IV | STAT | STAT | - | - | 10 mg IV slow push over 5-10 min; may repeat in 30 min | QT prolongation, Parkinson's | QTc, akathisia, dystonia |
| Metoclopramide IV | STAT | STAT | - | - | 10-20 mg IV over 15-30 min; may repeat in 30 min | QT prolongation, Parkinson's, seizures | QTc, akathisia, dystonia |
| Diphenhydramine IV | STAT | STAT | - | - | 25-50 mg IV to prevent akathisia (give with antiemetic) | Glaucoma, urinary retention | Sedation |
| Ketorolac IV | STAT | STAT | - | - | 30 mg IV (15 mg if >65y or CrCl <50); max 2 doses | Renal disease, GI bleeding, anticoagulation | Renal function |
| Dexamethasone IV | URGENT | URGENT | - | - | 10 mg IV once (reduces recurrence) | Active infection, uncontrolled DM | Glucose |
| Magnesium sulfate IV | URGENT | URGENT | - | - | 2 g IV over 20-30 min | Renal failure, myasthenia | Mg levels, reflexes |
| Valproate sodium IV | URGENT | URGENT | - | - | 500-1000 mg IV over 15-30 min | Pregnancy, hepatic disease, mitochondrial disease | Ammonia, LFTs |

### 3E. ED/Inpatient - Refractory/Second-Line Therapy (DHE Protocol)

**Prerequisites:** Check ECG, BP <140/90, negative pregnancy test. Avoid if triptan within 24h or CAD/CVA history.

| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |
|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|
| Dihydroergotamine (DHE) | URGENT | STAT | - | - | Premedicate: metoclopramide 10 mg IV + diphenhydramine 25 mg IV; Test dose: 0.5 mg IV over 1 min; If tolerated: 0.5-1 mg IV q8h | Pregnancy, CAD, CVA, uncontrolled HTN, triptan <24h, ergot allergy | BP, chest pain, nausea |
| DHE nasal | - | ROUTINE | ROUTINE | - | 0.5 mg per nostril (1 mg total); may repeat once in 15 min; max 3 mg/24h | Same as IV | Same |

### 3F. Pregnancy-Safe Options

| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |
|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|
| Acetaminophen | STAT | STAT | ROUTINE | - | 1000 mg PO/IV q8h; max 3000 mg/day | Hepatic disease | LFTs |
| Metoclopramide | STAT | STAT | ROUTINE | - | 10 mg IV/PO q8h | Parkinson's | Akathisia |
| Ondansetron | URGENT | ROUTINE | ROUTINE | - | 4-8 mg IV/PO q8h | QT prolongation (caution 1st trimester) | QTc |
| Magnesium sulfate | URGENT | URGENT | - | - | 2 g IV once | Renal failure | Reflexes, respiratory |
| Nerve block (occipital) | - | ROUTINE | ROUTINE | - | Lidocaine 1% or bupivacaine 0.25%, 2-3 mL per side | Local anesthetic allergy | Local reaction |
| Sumatriptan (if refractory) | - | EXT | EXT | - | 6 mg SC x1 (pregnancy registry data reassuring) | Per triptan list; discuss risks | Standard |

### 3G. Preventive Medications - First-Line

| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |
|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|
| Propranolol | - | ROUTINE | ROUTINE | - | Start 40-80 mg/day in divided doses; target 80-240 mg/day | Asthma, heart block, bradycardia, depression | HR, BP |
| Metoprolol | - | ROUTINE | ROUTINE | - | Start 25-50 mg BID; target 100-200 mg/day | Same as propranolol | HR, BP |
| Topiramate | - | ROUTINE | ROUTINE | - | Start 25 mg QHS; increase by 25 mg/week to 50-100 mg BID | Kidney stones, pregnancy (teratogenic), glaucoma | Bicarbonate, cognitive effects |
| Amitriptyline | - | ROUTINE | ROUTINE | - | Start 10-25 mg QHS; target 50-150 mg QHS | Glaucoma, urinary retention, cardiac arrhythmia | QTc, anticholinergic effects |
| Venlafaxine XR | - | ROUTINE | ROUTINE | - | Start 37.5 mg daily; target 75-150 mg daily | Uncontrolled HTN, MAOI use | BP, serotonin syndrome |

### 3H. Preventive Medications - CGRP Monoclonal Antibodies

| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |
|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|
| Erenumab (Aimovig) | - | - | ROUTINE | - | 70-140 mg SC monthly | Hypersensitivity; caution with constipation, HTN | BP, constipation |
| Fremanezumab (Ajovy) | - | - | ROUTINE | - | 225 mg SC monthly OR 675 mg SC quarterly | Hypersensitivity | Injection site reactions |
| Galcanezumab (Emgality) | - | - | ROUTINE | - | 240 mg SC loading, then 120 mg SC monthly | Hypersensitivity | Injection site reactions |
| Eptinezumab (Vyepti) | - | ROUTINE | ROUTINE | - | 100-300 mg IV q3 months | Hypersensitivity | Infusion reactions |

### 3I. Preventive Medications - Other

| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |
|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|
| Valproate | - | ROUTINE | ROUTINE | - | Start 250-500 mg BID; target 500-1500 mg/day | Pregnancy, hepatic disease | LFTs, ammonia |
| OnabotulinumtoxinA (Botox) | - | - | ROUTINE | - | 155-195 units IM q12 weeks (chronic migraine only) | Infection at injection sites, myasthenia | Spread of toxin effect |
| Atogepant (Qulipta) | - | - | ROUTINE | - | 10-60 mg PO daily | Severe hepatic impairment | LFTs |
| Rimegepant (preventive) | - | - | ROUTINE | - | 75 mg every other day | CYP3A4 inhibitors | LFTs |
| Magnesium oxide | - | ROUTINE | ROUTINE | - | 400-600 mg PO daily | Renal failure | Diarrhea |
| Riboflavin (Vitamin B2) | - | - | ROUTINE | - | 400 mg PO daily | None significant | None |
| CoQ10 | - | - | ROUTINE | - | 100 mg TID | None significant | None |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU | Indication |
|----------------|:--:|:----:|:---:|:---:|------------|
| Neurology consult | URGENT | ROUTINE | - | - | Status migrainosus, refractory to ED treatment |
| Headache specialist referral | - | ROUTINE | ROUTINE | - | Chronic migraine, medication overuse, refractory disease |
| Ophthalmology consult | URGENT | URGENT | ROUTINE | - | Papilledema, visual symptoms suggesting IIH |
| Pain management referral | - | - | ROUTINE | - | Refractory chronic migraine, nerve block consideration |
| Behavioral health referral | - | ROUTINE | ROUTINE | - | Comorbid anxiety/depression, biofeedback interest |
| Physical therapy | - | - | ROUTINE | - | Cervicogenic component, trigger point therapy |

### 4B. Patient/Family Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Keep headache diary (frequency, severity, triggers, medications) | ROUTINE | ROUTINE | ROUTINE |
| Treat migraine early - medications more effective within first hour | ROUTINE | ROUTINE | ROUTINE |
| Avoid medication overuse: limit triptans to ≤9 days/month, NSAIDs to ≤14 days/month | ROUTINE | ROUTINE | ROUTINE |
| Identify and avoid personal triggers | ROUTINE | ROUTINE | ROUTINE |
| Follow up with neurologist in 2-4 weeks if new diagnosis | ROUTINE | ROUTINE | ROUTINE |
| Follow up with PCP or neurologist for preventive medication monitoring | - | ROUTINE | ROUTINE |
| Return to ED if: worst headache of life, fever, neurologic deficits, altered mental status | ROUTINE | ROUTINE | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Maintain regular sleep schedule (7-8 hours) | - | ROUTINE | ROUTINE |
| Regular exercise (30 min, 5 days/week) | - | ROUTINE | ROUTINE |
| Stress management (biofeedback, relaxation techniques, CBT) | - | ROUTINE | ROUTINE |
| Stay well-hydrated (64+ oz water daily) | ROUTINE | ROUTINE | ROUTINE |
| Avoid known triggers: alcohol, aged cheese, MSG, processed meats, irregular meals | - | ROUTINE | ROUTINE |
| Limit caffeine to consistent moderate intake (<200 mg/day) | - | ROUTINE | ROUTINE |
| Consider migraine glasses (FL-41 tint) for photophobia | - | - | ROUTINE |

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Tension-type headache | Bilateral, pressing/tightening, mild-moderate, no nausea/vomiting | Clinical history; no photophobia |
| Cluster headache | Unilateral periorbital, autonomic features (tearing, rhinorrhea), short duration (15-180 min), circadian pattern | Clinical pattern; response to O2/triptans |
| Medication overuse headache | Chronic daily headache, >15 days/month, frequent analgesic use | Medication diary; improves with withdrawal |
| Subarachnoid hemorrhage | Thunderclap onset, "worst headache of life," neck stiffness | CT head, LP if CT negative |
| Idiopathic intracranial hypertension | Papilledema, visual obscurations, pulsatile tinnitus, bilateral pressure | LP with elevated OP (>25 cm H2O) |
| Giant cell arteritis | Age >50, new headache, jaw claudication, scalp tenderness, visual symptoms | ESR/CRP elevated, temporal artery biopsy |
| Cerebral venous thrombosis | Progressive headache, seizures, focal deficits, pregnancy/OCP | MRV/CTV |
| Cervicogenic headache | Neck pain, limited ROM, triggered by neck movement | Cervical exam, imaging |
| Trigeminal autonomic cephalalgia | Short attacks, autonomic features, response to indomethacin (some types) | Clinical pattern |
| Brain tumor | Progressive headache, worse in morning/with Valsalva, focal deficits | MRI brain |

## 6. MONITORING PARAMETERS

| Parameter | ED | HOSP | OPD | ICU | Frequency | Target/Threshold | Action if Abnormal |
|-----------|:--:|:----:|:---:|:---:|-----------|------------------|-------------------|
| Pain scale (0-10) | STAT | q4h | Each visit | - | Per assessment | Improving trend | Escalate treatment |
| Vital signs | STAT | q4h | Each visit | - | Per assessment | Normal | Address abnormalities |
| ECG (if using DHE/triptans) | STAT | STAT | - | - | Before administration | Normal QTc, no ischemia | Avoid vasoactive drugs |
| Headache diary | - | Daily | Each visit | - | Ongoing | Reduced frequency | Adjust preventive |
| MIDAS score | - | - | q3 months | - | Quarterly | Improving disability | Adjust treatment |
| Medication use tracking | - | ROUTINE | Each visit | - | Ongoing | No overuse | Address MOH |

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Discharge from ED | Pain controlled, able to tolerate PO, no red flags, close follow-up arranged |
| Admit to hospital | Status migrainosus unresponsive to ED treatment, need for DHE protocol, unable to tolerate PO, severe dehydration, concern for secondary headache |
| ICU admission | Rare - suspected intracranial pathology, hemodynamic instability |
| Discharge from hospital | Pain controlled on oral medications, tolerating PO, ambulatory |
| Outpatient follow-up | New diagnosis: 2-4 weeks; Chronic migraine: q1-3 months; On preventive: q3-6 months after stable |

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| Triptans effective for acute migraine | Class I, Level A | Cochrane Reviews; AHS Guidelines |
| Prochlorperazine/metoclopramide effective for acute migraine | Class I, Level A | Friedman et al., Neurology 2015 |
| Dexamethasone reduces headache recurrence | Class I, Level A | Singh et al., Cephalalgia 2008 |
| DHE effective for status migrainosus | Class II, Level B | Raskin, Headache 1986 |
| Beta-blockers effective for prevention | Class I, Level A | AAN Guidelines 2012 |
| Topiramate effective for prevention | Class I, Level A | AAN Guidelines 2012 |
| CGRP mAbs effective for prevention | Class I, Level A | Multiple RCTs; FDA approved 2018+ |
| OnabotulinumtoxinA for chronic migraine | Class I, Level A | PREEMPT trials; Aurora 2010 |
| Gepants effective for acute and preventive treatment | Class I, Level A | Multiple RCTs 2019-2023 |
| Avoid medication overuse | Class II, Level B | Headache Classification Committee, ICHD-3 |

---

## NOTES

- Migraine is a clinical diagnosis; imaging indicated only for red flags or atypical features
- Treat early - medications more effective when taken at onset
- Medication overuse is common cause of chronic daily headache; taper offending agents
- Consider preventive therapy if ≥4 migraine days/month, significant disability, or acute medications ineffective/overused
- CGRP antagonists (gepants and mAbs) are first-line options without cardiovascular contraindications
- Triptan cardiovascular contraindications are based on theoretical risk; reassuring real-world data for many patients
- Pregnancy: Acetaminophen, metoclopramide, and nerve blocks are safest; discuss triptan use case-by-case

---

## CHANGE LOG

**v1.0 (January 29, 2026)**
- Initial template creation
- Comprehensive acute and preventive treatment options
- Added CGRP antagonists (gepants) and monoclonal antibodies
- DHE protocol with prerequisites
- Pregnancy-safe options section
- Status migrainosus "headache cocktail" protocol
